/
Oncology
Advanced Solid Tumors Cancer
12
Pipeline Programs↗
5
Active Trials↗
13
Companies Involved↗
Advanced Solid Tumors Cancer is an emerging landscape with 12 programs across 13 companies. The most active players are Orionis Biosciences Inc, Grit Biotechnology.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical11
Phase 11
Phase 2
No programs
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
82%
Small molecule
9 of 11 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 11 classified programs, each share of the total. Modality classified for 92% of 12 pipeline programs.
Analysis
Trial Status
5
clinical trials
Recruiting3 · 60%
Not yet recruiting2 · 40%
Clinical Trials
Trial Activity
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)